Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy
Paclitaxel (PTX) has been used for cancer treatment for decades and has become one of the most successful chemotherapeutics in the clinic and financially. However, serious problems with its use still exist, owing to its poor solubility and non-selective toxicity. With respect to these issues, recent...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2021.626910/full |
id |
doaj-57a22cdf28b244f4b972cc3467529c7c |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuan Ma Yuan Ma Yuan Ma Yuan Ma Sifan Yu Sifan Yu Sifan Yu Shuaijian Ni Shuaijian Ni Shuaijian Ni Shuaijian Ni Baoxian Zhang Baoxian Zhang Angela Chun Fai Kung Angela Chun Fai Kung Jin Gao Jin Gao Aiping Lu Aiping Lu Aiping Lu Aiping Lu Ge Zhang Ge Zhang Ge Zhang Ge Zhang |
spellingShingle |
Yuan Ma Yuan Ma Yuan Ma Yuan Ma Sifan Yu Sifan Yu Sifan Yu Shuaijian Ni Shuaijian Ni Shuaijian Ni Shuaijian Ni Baoxian Zhang Baoxian Zhang Angela Chun Fai Kung Angela Chun Fai Kung Jin Gao Jin Gao Aiping Lu Aiping Lu Aiping Lu Aiping Lu Ge Zhang Ge Zhang Ge Zhang Ge Zhang Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy Frontiers in Cell and Developmental Biology paclitaxel ligand small molecule antibody aptamer |
author_facet |
Yuan Ma Yuan Ma Yuan Ma Yuan Ma Sifan Yu Sifan Yu Sifan Yu Shuaijian Ni Shuaijian Ni Shuaijian Ni Shuaijian Ni Baoxian Zhang Baoxian Zhang Angela Chun Fai Kung Angela Chun Fai Kung Jin Gao Jin Gao Aiping Lu Aiping Lu Aiping Lu Aiping Lu Ge Zhang Ge Zhang Ge Zhang Ge Zhang |
author_sort |
Yuan Ma |
title |
Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy |
title_short |
Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy |
title_full |
Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy |
title_fullStr |
Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy |
title_full_unstemmed |
Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy |
title_sort |
targeting strategies for enhancing paclitaxel specificity in chemotherapy |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Cell and Developmental Biology |
issn |
2296-634X |
publishDate |
2021-03-01 |
description |
Paclitaxel (PTX) has been used for cancer treatment for decades and has become one of the most successful chemotherapeutics in the clinic and financially. However, serious problems with its use still exist, owing to its poor solubility and non-selective toxicity. With respect to these issues, recent advances have addressed the water solubility and tumor specificity related to PTX application. Many measures have been proposed to remedy these limitations by enhancing tumor recognition via ligand-receptor-mediated targeting as well as other associated strategies. In this review, we investigated various kinds of ligands that have emerged as PTX tumor-targeting tools. In particular, this article highlights small molecule-, protein-, and aptamer-functionalized conjugates and nanoparticles (NPs), providing a promising approach for PTX-based individualized treatment prospects. |
topic |
paclitaxel ligand small molecule antibody aptamer |
url |
https://www.frontiersin.org/articles/10.3389/fcell.2021.626910/full |
work_keys_str_mv |
AT yuanma targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT yuanma targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT yuanma targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT yuanma targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT sifanyu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT sifanyu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT sifanyu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT shuaijianni targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT shuaijianni targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT shuaijianni targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT shuaijianni targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT baoxianzhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT baoxianzhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT angelachunfaikung targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT angelachunfaikung targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT jingao targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT jingao targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT aipinglu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT aipinglu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT aipinglu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT aipinglu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT gezhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT gezhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT gezhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy AT gezhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy |
_version_ |
1724199064018354176 |
spelling |
doaj-57a22cdf28b244f4b972cc3467529c7c2021-03-29T05:37:37ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2021-03-01910.3389/fcell.2021.626910626910Targeting Strategies for Enhancing Paclitaxel Specificity in ChemotherapyYuan Ma0Yuan Ma1Yuan Ma2Yuan Ma3Sifan Yu4Sifan Yu5Sifan Yu6Shuaijian Ni7Shuaijian Ni8Shuaijian Ni9Shuaijian Ni10Baoxian Zhang11Baoxian Zhang12Angela Chun Fai Kung13Angela Chun Fai Kung14Jin Gao15Jin Gao16Aiping Lu17Aiping Lu18Aiping Lu19Aiping Lu20Ge Zhang21Ge Zhang22Ge Zhang23Ge Zhang24Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongIncreasepharm (Hong Kong) Limited, Hong Kong Science Park, Shatin, Hong KongIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongIncreasepharm (Hong Kong) Limited, Hong Kong Science Park, Shatin, Hong KongIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongIncreasepharm (Hengqin) Institute Co. Limited, Zhuhai, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongPaclitaxel (PTX) has been used for cancer treatment for decades and has become one of the most successful chemotherapeutics in the clinic and financially. However, serious problems with its use still exist, owing to its poor solubility and non-selective toxicity. With respect to these issues, recent advances have addressed the water solubility and tumor specificity related to PTX application. Many measures have been proposed to remedy these limitations by enhancing tumor recognition via ligand-receptor-mediated targeting as well as other associated strategies. In this review, we investigated various kinds of ligands that have emerged as PTX tumor-targeting tools. In particular, this article highlights small molecule-, protein-, and aptamer-functionalized conjugates and nanoparticles (NPs), providing a promising approach for PTX-based individualized treatment prospects.https://www.frontiersin.org/articles/10.3389/fcell.2021.626910/fullpaclitaxelligandsmall moleculeantibodyaptamer |